Related Experiment Video
Updated: May 26, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Are multimetabolite methods fit-for-purpose for supporting toxicology studies?
1Department of Bioanalysis, Huntingdon Life Sciences, Woolley Road, Alconbury, Huntingdon, Cambridgeshire, UK. smithg@ukorg.huntingdon.com
Bioanalysis
|December 22, 2011
Summary
Measuring drug metabolites is crucial in drug development. However, industry practice often involves quantifying metabolites even when not required by regulatory guidelines, potentially wasting resources.
Area of Science:
- Pharmacokinetics and Drug Metabolism
- Bioanalytical Chemistry
- Regulatory Science
Background:
- Parent drug measurement is essential throughout drug development.
- Regulatory guidelines mandate metabolite exposure data for drug registration.
- Industry practices sometimes deviate from regulatory requirements for metabolite analysis.
Purpose of the Study:
- To discuss the necessity and strategy of measuring drug metabolites during drug development.
- To evaluate the current industry consensus versus regulatory guidelines on metabolite quantification.
- To highlight the resource implications of broad metabolite analysis in early development.
Main Methods:
- Review of regulatory guidelines on metabolite safety testing.
- Analysis of industry practices in bioanalytical method validation for metabolites.
- Discussion of resource allocation in early drug development studies.
Main Results:
- A discrepancy exists between regulatory requirements and industry practice regarding metabolite measurement.
- Early development studies may involve quantifying numerous metabolites using fully validated methods.
- This broad approach can lead to inefficient resource utilization.
Conclusions:
- Metabolite measurement decisions should align with drug development stage and regulatory needs.
- A targeted approach to metabolite analysis is more efficient for early development.
- Resource optimization is key, especially in early-phase drug development.
More Related Videos
Related Concept Videos
01:23Toxicity Testing in Animals
Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
01:21Toxicokinetics: Overview
Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
01:25Bioactivation and Tissue Toxicity
Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
01:25Mutagenicity and Carcinogenicity
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
01:24Drug Toxicity: Dose-Dependent Reactions
Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...